A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline from Stage I Invasive Ovarian Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

September 3, 2029

Study Completion Date

September 3, 2029

Conditions
Stage I Ovarian CancerBorderline Ovarian Tumors
Trial Locations (1)

3000

UZ Leuven, Leuven

All Listed Sponsors
lead

KU Leuven

OTHER